“Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma” has been added to your cart. View cart

Article: P16 Real-Life Experience with Brentuximab Vedotin (Adcetris®): the Belgian National Registry

€3.03

SKU: product-article-16360 Category: General

Description
Reviews (0)

Description

P16 Real-Life Experience with Brentuximab Vedotin (Adcetris®): the Belgian National Registry

Reviews

There are no reviews yet.

Be the first to review “Article: P16 Real-Life Experience with Brentuximab Vedotin (Adcetris®): the Belgian National Registry”

You must be logged in to post a review.

Top

Article: P16 Real-Life Experience with Brentuximab Vedotin (Adcetris®): the Belgian National Registry

Description

Reviews

Related products

Article: Highlights in melanoma

Article: Highlights in urologic cancer

Article: Highlights in gynaecological cancers

Article: Highlights in respiratory oncology